ERASCA INC. - COMMON STOCK

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

01 May 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

26 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

25 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development

10 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates

23 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting

14 Mar 2023 15:31:00 By Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Oncology Conference 2023

01 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors

20 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

13 Dec 2022 07:00:02 By Nasdaq GlobeNewswire

Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib

09 Dec 2022 06:34:39 By Nasdaq GlobeNewswire

Erasca Announces Pricing of Underwritten Offering of Common Stock

09 Dec 2022 06:32:35 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

30 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

22 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca Reports Third Quarter 2022 Financial Results and Business Updates

09 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination

20 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium

12 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022

26 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Erasca to Present at the Morgan Stanley Global Healthcare Conference

09 Sep 2022 07:31:53 By Nasdaq GlobeNewswire